- Home
- SLNH vs FATE Comparison
SLNH vs FATE Comparison
Compare SLNH & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNH | FATE |
|---|---|---|
| Founded | 1961 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.2M | 139.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | SLNH | FATE |
|---|---|---|
| Price | $1.03 | $1.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $5.00 | $3.92 |
| AVG Volume (30 Days) | ★ 6.2M | 1.8M |
| Earning Date | 11-17-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,782,000.00 | $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.66 |
| 52 Week High | $5.14 | $1.94 |
Technical Indicators
Market Signals| Indicator | SLNH | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 45.91 |
| Support Level | $0.75 | $1.04 |
| Resistance Level | $1.16 | $1.26 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 12.72 | 14.36 |
Price Performance
Historical ComparisonAbout SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.